Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for BridgeBio Pharma

    Client Virtual Booth

    BRIDGEBIO PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    BridgeBio Pharma
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    421 Kipling Street, Palo Alto, CA 94301
    Telephone
    Telephone
    650-391-9740
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://bridgebio.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/bridgebio
    Twitter
    Twitter
    https://twitter.com/hashtag/bridgebio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    https://www.globenewswire.com/news-release/2024/04/10/2860649/0/en/BridgeBio-Pharma-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    10 Apr 2024
    Share Share
    BridgeBio Presents Data of ATTRibute-CM Ph 3 Study with Transthyretin ATTR-CM
    BridgeBio Presents Data of ATTRibute-CM Ph 3 Study with Transthyretin ATTR-CM

    https://www.globenewswire.com/news-release/2024/04/07/2858836/0/en/BridgeBio-Pharma-Presents-Cardiac-Magnetic-Resonance-CMR-Imaging-Evidence-Consistent-with-Clinical-Improvement-Observed-in-the-ATTRibute-CM-Phase-3-Study-in-Patients-with-Transthyr.html

    GLOBENEWSWIRE
    07 Apr 2024
    Share Share
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    https://www.globenewswire.com/news-release/2024/03/20/2849270/0/en/BridgeBio-Pharma-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    20 Mar 2024
    Share Share
    Bayer buys European rights to BridgeBio's ATTR-CM pill
    Bayer buys European rights to BridgeBio's ATTR-CM pill

    https://endpts.com/bayer-buys-european-rights-to-bridgebios-attr-cm-pill/

    ENDPTS
    05 Mar 2024
    Share Share
    bridgebio pharma announces pricing of public offering of common stock
    bridgebio pharma announces pricing of public offering of common stock

    https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-pricing-public-offering-common-0

    PRESS RELEASE
    05 Mar 2024
    Share Share
    BridgeBio Pharma Announces Proposed Public Offering of Common Stock
    BridgeBio Pharma Announces Proposed Public Offering of Common Stock

    https://www.globenewswire.com//news-release/2024/03/04/2839991/0/en/BridgeBio-Pharma-Announces-Proposed-Public-Offering-of-Common-Stock.html

    GLOBENEWSWIRE
    04 Mar 2024
    Share Share
    BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
    BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

    https://www.globenewswire.com//news-release/2024/02/22/2833578/0/en/BridgeBio-Pharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Business-Update.html

    GLOBENEWSWIRE
    22 Feb 2024
    Share Share
    For $100M, BridgeBio partners with Kyowa Kirin on infigratinib
    For $100M, BridgeBio partners with Kyowa Kirin on infigratinib

    https://www.fiercepharma.com/pharma/kyowa-kirin-pays-100m-partner-bridgebio-potential-dwarfism-drug

    FIERCE PHARMA
    07 Feb 2024
    Share Share
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    https://www.globenewswire.com//news-release/2024/02/06/2824201/0/en/BridgeBio-Pharma-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    06 Feb 2024
    Share Share
    BridgeBio Pharma Announces FDA Acceptance of NDA for Acoramidis
    BridgeBio Pharma Announces FDA Acceptance of NDA for Acoramidis

    https://www.globenewswire.com//news-release/2024/02/05/2823433/0/en/BridgeBio-Pharma-Announces-U-S-Food-and-Drug-Administration-FDA-Acceptance-of-New-Drug-Application-NDA-for-Acoramidis-for-the-Treatment-of-Patients-with-Transthyretin-Amyloid-Cardi.html

    GLOBENEWSWIRE
    05 Feb 2024
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search